Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Childhood leukemias--current status and future perspective

C H Pui1

  • 1Department of Hematology/Oncology, St. Jude Children's Hospital, Memphis, TN 38105, USA.

Zhonghua Minguo Xiao Er Ke Yi Xue Hui Za Zhi [Journal]. Zhonghua Minguo Xiao Er Ke Yi Xue Hui
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood.

Leukemia & lymphoma·2016
Same author

A revised definition for cure of childhood acute lymphoblastic leukemia.

Leukemia·2014
Same author

Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

Cancer chemotherapy and pharmacology·2014
Same author

Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL).

Pediatric blood & cancer·2014
Same author

Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.

Journal of the National Cancer Institute·2012

Current treatments cure most childhood acute lymphoblastic leukemia (ALL) but not acute myeloid leukemia (AML). Research aims to personalize leukemia therapies based on risk and specific subtypes for better outcomes.

Area of Science:

  • Pediatric Hematology Oncology
  • Cancer Genomics
  • Translational Medicine

Background:

  • Acute lymphoblastic leukemia (ALL) has a high cure rate in children, but risk-directed therapy is crucial for optimizing outcomes.
  • Acute myeloid leukemia (AML) in children has a poor prognosis, with only 30-40% long-term survival despite intensive treatments.
  • Chronic myeloid leukemia (CML) treatment relies on allogeneic bone marrow transplantation as the only curative option.

Purpose of the Study:

  • To enhance treatment strategies for childhood leukemias by focusing on risk-directed and subtype-specific approaches.
  • To explore the potential of targeted therapies based on specific genetic lesions in leukemic cells.
  • To improve survival rates and reduce treatment complications in pediatric leukemia patients.

Main Methods:

Related Experiment Videos

  • Review of current treatment paradigms for childhood ALL, AML, and CML.
  • Analysis of research identifying patient subgroups with differential responses to therapy.
  • Exploration of targeted treatment strategies based on leukemia subtypes and genetic mutations.

Main Results:

  • Risk-directed therapy can improve outcomes for high-risk ALL patients while minimizing toxicity for low-risk patients.
  • Identification of specific biologic subtypes in AML that predict response to targeted therapies.
  • Allogeneic bone marrow transplantation remains the cornerstone of curative treatment for CML.

Conclusions:

  • Personalized treatment approaches, including risk-directed and subtype-specific therapies, are essential for improving childhood leukemia outcomes.
  • Future research should focus on leveraging genetic information to develop highly targeted treatments for leukemic cells.
  • Advancing precision medicine in pediatric leukemia holds promise for increasing cure rates and reducing long-term treatment sequelae.